contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


the-nomination-committees-revised-proposal-before-the-annual-general-meeting-2024

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

C-Rad is active in medical technology. The company conducts the development, manufacturing, and sales of products and solutions in advanced radiation therapy. The business is mainly aimed at clinics that offer radiation treatment, where the company in addition to its core business offers associated installation services and support. The customers are located on a global level and the head office is located in Uppsala.

C-Rad

The Nomination Committee of C-RAD AB (publ) has decided to propose that the Annual General Meeting 2024 approves the following revised proposals regarding the number of Board members and election...

<div class="mfn-body"><p>The Nomination Committee of C-RAD AB (publ) has decided to propose that the Annual General Meeting 2024 approves the following revised proposals regarding the number of Board members and election of the Board of Directors.</p><p>The Nomination Committee proposes that the Board of Directors should consist of six Board members elected by the General Meeting, without Deputies, for the period until the next Annual General Meeting.</p><p>The Nomination Committee proposes re-election of Jenny Rosberg, David Sjöström, Kristina Willgård, Susanne Ekblom and Peter Simonsbacka, and election of Mats Thorén as Board members for the period until the next Annual General Meeting. Kristina Willgård is proposed to be re-elected as Chair of the Board of Directors for the period until the next Annual General Meeting.</p><p>Mats Thorén, born in 1971, has solid experience from the financial market, primarily focused on the life science sector as an analyst and in corporate finance. He is CEO and Board member of the company Vixco Capital AB as well as Board member of Arcoma AB, Arcoma Incentive AB, Herantis Pharma Oyj, FluoGuide A/S and Xbrane Biopharma AB as well as Deputy of Eggelbertus Holding AB and has previous experience as a Board member of C-RAD AB (publ) and Nalka Life Science AB. Mats Thorén studied at Stockholm School of Economics and studied medicine at Karolinska Institutet in Stockholm. Mats Thorén is independent in relation to the company and company management as well as independent in relation to the company's major shareholders and he owns no shares in the company.</p><p>Information concerning the current Board members who are proposed for re-election is available on the company's website, <a rel="noopener" href="http://www.c-rad.com">www.c-rad.com</a></p><p>As the Nomination Committee's revised proposal includes six Board members instead of the previous five Board members, the total Board fee amounts to a total of SEK 1,720,000, in accordance with the Nomination Committee’s proposal.</p><p>The Annual General Meeting will be held on May 15, 2024.</p></div><div class="mfn-footer mfn-contacts mfn-e520b92ae86a"><p><strong class="mfn-heading-1">For further information:</strong></p><hr><p>Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, <a rel="noopener" href="mailto:investors@c-rad.com">investors@c-rad.com</a></p></div><div class="mfn-footer mfn-about mfn-1fc3b360975a"><p><strong class="mfn-heading-1">About C-RAD</strong></p><hr><p>C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.</p><p>C-RAD. Inspiring excellence in cancer treatment.</p><p>C-RAD AB is listed on NASDAQ Stockholm.</p><p>For more information on C-RAD, please visit&nbsp;<a rel="noopener" href="http://www.c-rad.com/">http://www.c-rad.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/c63dd571-a744-4e95-ba2d-f890060dad6a/the-nomination-committees-revised-proposal-before-the-annual-general-meeting-2024.pdf" class="mfn-generated mfn-primary">The Nomination Committee’s revised proposal before the Annual General Meeting 2024</a></p></div>

The Nomination Committee’s revised proposal before the Annual General Meeting 2024

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!